Suppr超能文献

基于结构的 SARS-CoV-2 3CL 蛋白酶强效抑制剂设计:结构、生化和基于细胞的研究。

Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies.

机构信息

Department of Chemistry, Wichita State University, Wichita, Kansas 67260, United States.

Department of Diagnostic Medicine & Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas 66506, United States.

出版信息

J Med Chem. 2021 Dec 23;64(24):17846-17865. doi: 10.1021/acs.jmedchem.1c01037. Epub 2021 Dec 5.

Abstract

The COVID-19 pandemic is having a major impact on public health worldwide, and there is an urgent need for the creation of an armamentarium of effective therapeutics, including vaccines, biologics, and small-molecule therapeutics, to combat SARS-CoV-2 and emerging variants. Inspection of the virus life cycle reveals multiple viral- and host-based choke points that can be exploited to combat the virus. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for therapeutic intervention, and the design of inhibitors of the protease may lead to the emergence of effective SARS-CoV-2-specific antivirals. We describe herein the results of our studies related to the application of X-ray crystallography, the Thorpe-Ingold effect, deuteration, and stereochemistry in the design of highly potent and nontoxic inhibitors of SARS-CoV-2 3CLpro.

摘要

COVID-19 大流行正在对全球公共卫生产生重大影响,迫切需要开发有效的治疗方法,包括疫苗、生物制剂和小分子治疗药物,以对抗 SARS-CoV-2 和新出现的变体。对病毒生命周期的检查揭示了多个可以利用的病毒和宿主基础的关键点,以对抗病毒。SARS-CoV-2 3C 样蛋白酶(3CLpro)是一种对病毒复制至关重要的酶,是治疗干预的一个有吸引力的靶点,设计蛋白酶抑制剂可能会导致出现有效的 SARS-CoV-2 特异性抗病毒药物。本文介绍了我们应用 X 射线晶体学、Thorpe-Ingold 效应、氘化和立体化学设计高活性和无毒 SARS-CoV-2 3CLpro 抑制剂的研究结果。

相似文献

5
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.SARS-CoV-2 主蛋白酶抑制剂的发现与作用机制。
J Med Chem. 2022 Feb 24;65(4):2866-2879. doi: 10.1021/acs.jmedchem.1c00566. Epub 2021 Sep 27.

引用本文的文献

5
On the origins of SARS-CoV-2 main protease inhibitors.关于严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂的起源
RSC Med Chem. 2023 Oct 13;15(1):81-118. doi: 10.1039/d3md00493g. eCollection 2024 Jan 25.
8
Deuterium in drug discovery: progress, opportunities and challenges.药物发现中的氘代:进展、机遇与挑战。
Nat Rev Drug Discov. 2023 Jul;22(7):562-584. doi: 10.1038/s41573-023-00703-8. Epub 2023 Jun 5.

本文引用的文献

3
SARS-CoV-2 variants and ending the COVID-19 pandemic.严重急性呼吸综合征冠状病毒2变体与终结2019冠状病毒病大流行
Lancet. 2021 Mar 13;397(10278):952-954. doi: 10.1016/S0140-6736(21)00370-6. Epub 2021 Feb 11.
9
The SARS-CoV-2 main protease as drug target.SARS-CoV-2 主要蛋白酶作为药物靶点。
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127377. doi: 10.1016/j.bmcl.2020.127377. Epub 2020 Jul 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验